3.1 Prescription Drug Benefit Design & PBM Operations

Architecture of Prescription Drug Benefits

Prescription drug benefits represent one of the most visible, high-frequency, and rapidly escalating components of modern employer-sponsored health programs. Historically, prescription drugs were reimbursed under major medical policies as basic indemnity expenses, requiring employees to pay out of pocket, collect paper receipts, and submit manual claims subject to the major medical deductible and coinsurance. Today, prescription drug coverage is almost universally delivered through a specialized, managed prescription drug program administered by a Pharmacy Benefit Manager (PBM).

Plan sponsors generally structure prescription drug benefits under one of two operational configurations:

1. Carve-In Arrangements: The prescription drug benefit is bundled directly within the major medical plan contract through a commercial health insurance carrier or third-party administrator (TPA). While the medical carrier may subcontract underlying pharmacy administration to an affiliated or captive PBM (e.g., Evernorth/Cigna, Caremark/CVS Health, OptumRx/UnitedHealth), the plan sponsor maintains a single contract, integrated deductible, and combined customer service interface.
2. Carve-Out Arrangements: The plan sponsor contracts directly with an independent PBM to manage pharmacy benefits separately from the medical plan. Carve-out arrangements allow self-funded employers to negotiate customized formulary designs, direct manufacturer rebate pass-through terms, tailored clinical utilization programs, and independent audit rights.

At the core of PBM operations is real-time electronic point-of-sale (POS) claims adjudication. When a plan participant presents a prescription at a participating retail pharmacy, the pharmacy management system transmits encrypted transaction data using National Council for Prescription Drug Programs (NCPDP) standards to the PBM's adjudication engine. Within milliseconds, the PBM verifies member eligibility, checks formulary status, calculates patient cost-sharing (copayment or coinsurance), performs automated Drug Utilization Review (DUR) for contraindications and drug-drug interactions, and transmits the approved reimbursement amount back to the dispensing pharmacist.

---

Formulary Design & Incentive Tier Structures

A formulary is an evidence-based, continually updated compendium of prescription medications approved for coverage under the health plan. Formularies are developed and maintained by a Pharmacy & Therapeutics (P&T) Committee, comprised of independent practicing physicians, clinical pharmacists, and pharmacoeconomic experts. The P&T committee evaluates peer-reviewed clinical trial data, FDA labeling, therapeutic efficacy, safety profiles, and clinical guidelines before considering financial net-cost factors.

Types of Formulary Architecture

• Open Formulary: The plan provides coverage for virtually all FDA-approved prescription drugs, with minimal exclusions. While member choice is maximized, cost containment is extremely weak because the plan lacks leverage to negotiate manufacturer rebates or redirect utilization to lower-cost therapeutic equivalents.
• Closed Formulary: The plan exclusively covers medications listed on the formulary. Non-formulary medications receive zero plan reimbursement, requiring the member to pay 100% of the retail cost unless an exception is granted through a formal medical necessity appeal.
• Incentive / Tiered Formulary: The dominant model in employer benefit design. Rather than excluding non-preferred medications outright, the plan establishes variable cost-sharing tiers that financially motivate participants and prescribers to choose clinically effective, lower-cost medications.

---

PBM Revenue Models & Contracting Dynamics

Plan sponsors evaluating PBM contracts must navigate complex financial arrangements that govern how PBMs generate revenue. The two primary financial contracting models are spread pricing and pass-through (transparent) pricing.

Spread Pricing vs. Pass-Through Transparent Pricing

• Spread Pricing (Traditional Model): The PBM contracts separately with the plan sponsor and network pharmacies. The PBM bills the plan sponsor an agreed-upon contracted rate (e.g., Average Wholesale Price [AWP] minus 18% plus a $2.00 dispensing fee) but reimburses the dispensing pharmacy a lower amount (e.g., AWP minus 22% plus a $1.00 dispensing fee). The PBM retains the difference—the spread—as profit. Under spread pricing, the plan sponsor has price predictability on paper but lacks visibility into the true acquisition cost of medications, particularly for generic drugs governed by proprietary Maximum Allowable Cost (MAC) lists.
• Pass-Through / Transparent Pricing: The PBM charges the plan sponsor the exact reimbursement amount paid to the network dispensing pharmacy, with zero markup or spread. In exchange, the plan sponsor pays a transparent, explicit administrative fee (e.g., $1.50–$3.50 per adjudicated claim). Pass-through contracts typically mandate 100% pass-through of all manufacturer rebates, discounts, and manufacturer administrative fees, supported by comprehensive audit rights.

Manufacturer Rebates & Revenue Streams

Pharmaceutical manufacturers pay substantial rebates to PBMs in exchange for favorable formulary placement (e.g., Tier 2 preferred status over a competitor's product) or exclusive formulary positioning. Rebates fall into three broad categories:

1. Formulary Access Rebates: Fixed percentage discounts paid on all dispensed units of a drug for securing inclusion on the formulary.
2. Market-Share / Volume Rebates: Tiered rebates that increase as the drug achieves specific market-share thresholds within its therapeutic class against competing drugs.
3. Price Protection Rebates: Penalties paid by the manufacturer to the PBM/plan sponsor if the manufacturer increases the wholesale acquisition cost (WAC) of the drug faster than a contractually defined benchmark (e.g., Consumer Price Index [CPI-U]).

In addition to rebates, PBMs may collect manufacturer administrative fees (typically 3%–5% of WAC), data-sharing fees, and clinical program management fees. Fiduciary best practice under ERISA requires plan sponsors to negotiate contract terms that capture all sources of revenue derived from plan volume.

---

Clinical Cost-Containment & Utilization Management Tools

To balance participant access to essential therapies with economic sustainability, plan sponsors and PBMs deploy targeted Utilization Management (UM) protocols:

• Prior Authorization (PA): Requires the prescribing physician to submit clinical documentation establishing that the patient meets specific evidence-based criteria before the PBM approves coverage. PA is commonly applied to high-cost medications, drugs with significant safety risks, or agents vulnerable to off-label overutilization.
• Step Therapy ('Fail-First' Protocols): Requires the patient to first try and fail a clinically proven, lower-cost first-line therapy (typically a generic medication) before the plan will approve coverage for a more expensive second-line or brand-name drug in the same therapeutic class.
• Quantity Limits (QL): Caps the number of dosage units dispensed within a defined timeframe (e.g., 30 tablets per 30 days or a maximum daily milligram dose). QLs align dispensing with FDA-approved dosing schedules, prevent waste, reduce stockpiling, and curb potential abuse (notably for opioids and controlled substances).
• Mandatory Generic Substitution & 'Dispense as Written' (DAW) Penalties: When a multi-source brand drug has an FDA-approved generic equivalent (AB-rated), the plan covers only the generic cost. If a participant elects to receive the brand-name drug (DAW 2), the member pays the standard Tier 1 copay plus the full financial difference between the brand acquisition cost and the generic acquisition cost.
• Mail-Order & 90-Day Retail Networks: For maintenance medications taken for chronic conditions (e.g., antihypertensives, statins), plans incentivize 90-day supplies through mail-order pharmacies or specialized retail networks ('Retail 90'). Plan sponsors benefit from deeper unit-cost discounts and lower aggregate dispensing fees, while members receive cost-sharing discounts (e.g., paying 2 monthly copays for a 3-month supply).

---

Specialty Pharmacy Management, Biologics & Emerging Solutions

Specialty pharmaceuticals—including recombinant proteins, monoclonal antibodies, cellular therapies, and gene therapies—represent less than 2%–3% of total prescription volume but account for more than 50% of total pharmacy expenditure in employer benefit plans. Specialty medications treat complex, chronic, or rare diseases such as rheumatoid arthritis, oncology, multiple sclerosis, and inflammatory bowel disease.

Biosimilars & Interchangeability

Unlike small-molecule generic drugs produced through chemical synthesis, biologics are complex, large-molecule proteins derived from living biological systems. Under the Biologics Price Competition and Innovation Act (BPCI Act), the FDA approves biosimilars via the 351(k) pathway upon demonstrating that the drug is highly similar to the reference biologic with no clinically meaningful differences in safety, purity, or potency.

An interchangeable biosimilar meets additional statutory standards, allowing pharmacists to substitute the biosimilar for the reference product at the pharmacy counter without prescriber intervention, subject to state pharmacy laws. The rapid emergence of biosimilars for blockbuster biologics (e.g., adalimumab, infliximab, trastuzumab) creates substantial savings opportunities when PBMs align formulary tiering to promote biosimilar adoption.

Site-of-Care Optimization

Many specialty infused biologics are billed under the medical benefit rather than the pharmacy benefit. When administered in a hospital outpatient department (HOPD), facility fees and hospital markups often inflate the cost to 200%–400% of the drug's acquisition cost. Site-of-Care Optimization programs mandate or incentivize the transition of stable patients from HOPDs to lower-cost, clinically equivalent settings, including ambulatory infusion centers (AICs), physician offices, or home infusion by specialized infusion nurses.

Copay Accumulator vs. Copay Maximizer Programs

To help patients manage high coinsurance on specialty drugs, pharmaceutical manufacturers offer commercial copay assistance cards (coupons). While these coupons alleviate short-term patient financial burden, they can undermine formulary tiering and accelerate plan deductible exhaustion. Employers deploy two primary strategies:

1. Copay Accumulator Adjustment Programs: The PBM allows the manufacturer coupon to pay the member's initial out-of-pocket costs at the pharmacy counter, but the coupon value does not count toward the member's annual deductible or Out-of-Pocket Maximum (OOPM). Once the coupon maximum dollar limit is exhausted, the patient must pay their full deductible and coinsurance out of pocket.
2. Copay Maximizer Programs: The plan reclassifies specialty medications as 'non-essential health benefits' (under ACA definitions) where permissible, setting the patient cost-sharing rate to match the exact maximum annual value of the manufacturer coupon divided across twelve months. The coupon covers 100% of the patient liability with $0 out of pocket for the member, and zero coupon dollars accrue to the medical OOPM, maximizing plan savings without imposing sudden mid-year financial shock on the employee.